Bruker Corporation reported its third‑quarter 2025 earnings, posting a non‑GAAP earnings per share of $0.45, beating the consensus estimate of $0.34 by 32%.
Revenue for the quarter was $860.5 million, surpassing analyst expectations of $845.7 million to $850.3 million and representing a 0.5% decline from the $864.4 million reported in Q3 2024.
Organic revenue fell 4.5% year‑over‑year. The Scientific Instruments segment recorded a 1.5% decline in revenue, with an organic drop of 5.4%, while the Energy & Supercon Technologies segment grew 7.4% year‑over‑year, with organic growth of 6.9%.
Non‑GAAP operating margin contracted to 12.3% from 14.9% a year earlier, driven by lower revenue absorption, additional tariff costs, and currency headwinds.
Bruker revised its full‑year 2025 guidance downward, projecting revenue of $3.41 billion to $3.44 billion and non‑GAAP EPS of $1.85 to $1.90, citing continued organic softness, late order bookings, and restructuring charges.
The company highlighted a mid‑single‑digit organic bookings growth year‑over‑year and a book‑to‑bill ratio above 1.0 in the Scientific Instruments segment, suggesting potential for future revenue improvement.
Bruker also reported a GAAP diluted loss per share of $(0.41) in Q3 2025, reflecting $119.4 million goodwill and intangibles impairment and $34.5 million restructuring charges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.